PARP1 and ovarian cancer: It was suggested that because EMSY amplification could mimic a BRCA2 mutated state [148], it could account for BRCAness in sporadic breast and ovarian cancers with intact BRCA2 [122] and possibly predict hypersensitivity to PARP inhibitors.